Immix Biopharma Investor Presentation Deck

TSTX Market Opportunity Annual Drug Sales (US$ billion) Company KeytrudaⓇ/ pembrolizumab MERCK $33.4bn combined OpdivoⓇ/ nivolumab Oncology (Soft tissue sarcoma, colorectal cancer) Bristol Myers Squibb AvastinⓇ/ bevacizumab Roche Cyramza Ⓡ/ ramucirumab Lilly $0.9bn combined VotrientⓇ/ pazopanib NOVARTIS ●●● IMMIX S BIOPHARMA Halaven Ⓡ/ YondelisⓇ/ eribulin trabectedin дад Eisai Source: Eisai FY2022 Financial Results Presentation, Novartis 2022 Annual Report, 2022 Merck Financial Results, 2022 Bristol Meyers Squibb Financial Results, Roche 2021 Investor Update, Eli Lilly 2022 Financial Results, Abbvie 2022 Financial Results, Johnson & Johnson 2022 Full Year Results, Takeda Annual Securities Report 48

View entire presentation